干扰灵联合免疫核糖核酸治疗慢性乙肝疗效分析

Clinical Analysis of the Effect with Interferon Alpha and Anti-HBV iRNA Therapy On Chronic Hepatitis B Virus Infection

采用干扰灵联合抗乙肝免疫核糖核酸治疗慢性乙肝２６例，并与１８例对照组比较。结果表明：治疗结束时，ＨＢｓＡｇ转阴率１５４％（４／２６），ＨＢｅＡｇ转阴率７７２％（１７／２２），ＨＢＶＤＮＡ转阴率５７７％（１５／２６），明显高于对照组（Ｐ＜０．０１）；随访一年１例患者ＨＢｅＡｇ、ＨＢＶＤＮＡ转阴，２例患者ＨＢｓＡｇ、ＨＢｅＡｇ、ＨＢＶＤＮＡ转阴后变阳，其有效率仍显著高于对照组（Ｐ＜０．０１）。上述结果表明：干扰灵联合抗乙肝免疫核糖核酸疗法能明显抑制ＨＢＶ复制，提高抗病毒疗效。本文并对影响抗病毒疗效的诸多因素进行了分析。

Twenty-six patients of chronic hepatitis B(CHB) with active viral replicaton were received interferon alpha and anti-HBV immune RNA(iRNA) therapy for three months,whereas compared with 18 patients as controlled trial.The results showed:At the end of therapy,HBsAg was not detectable in 4(15.4%) of the 26 treated patients,HBeAg wasn't present in 17(77.2%) of the 22 treatd patients with HBeAg-positive and 57.7%(15/26)was not detected HBV DNA in sera.these responses were exclusively associated with interferon alpha and anti-HBV iRNA therapy.After one year's follow-up,one patient became HBeAg negative,and HBV DNA wasn't found in serum,two patients who had been cleared HBsAg,HBeAg and HBV DNA after treated returned to HB sAg,HBeAg and HBV DNA positive.The efficacy of anti-HBV in treated group was much higher than that in cont-rolled group(P<0.01).These data suggest that interferon alpha and anti-HBV iRNA theapy can apparently inhibit HBV replication in CHB and improve clearance of HBV.The other several factors influencing clearance of HBV were discussed.